MannKind’s AFREZZA vs. Pfizer’s Exubera: Will Inhaled Insulin Be Different This Time?

With an FDA decision pending on Mannkind Corporation’s AFREZZA (TM)  (insulin human (rDNA origin) Inhalation Powder – formerly named AFRESA ) and the recent failure of the first inhaled insulin to receive FDA approval, we thought it would be helpful to provide an analytical approach to this emerging health technology. For those who are unfamiliar [...]

Exubera

On Thursday March 4, Aventis SA and Pfizer Inc. stated that the European Medicines Evaluation Agency has accepted the filing of a marketing authorization application for Exubera (human insulin powder). The companies are seeking approval to market Exubera for adult patients with Type 1 and Type 2 diabetes. Pfizer and Aventis have been working with [...]